CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


HP:0002315: HeadacheHPO

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (4)


Name (Synonyms) Correlation
drug1762 Mindfulness program Wiki 0.71
drug2787 Symptomatic drugs Wiki 0.71
drug470 Bridge therapy Wiki 0.71
drug1756 Mindfulness Wiki 0.50

Correlated MeSH Terms (4)


Name (Synonyms) Correlation
D006261 Headache NIH 1.00
D008881 Migraine Disorders NIH 0.82
D051271 Headache Disorders, Secondary NIH 0.71
D004630 Emergencies NIH 0.13

Correlated HPO Terms (1)


Name (Synonyms) Correlation
HP:0002076 Migraine HPO 0.82

There are 2 clinical trials

Clinical Trials


1 Feasibility and Effectiveness of Mindfulness Program by Smartphone for Patients With Chronic Migraine and Medication Overuse During Covid-19 Emergency

Chronic Migraine is a disabling condition that affects the 2% of migraine population. It is often associated with medication overuse that makes this condition very difficult to treat. The literature of the last decades confirm the efficacy of withdrawal for patients with medication overuse but it is also confirmed that patients have to be carefully followed in the last period after withdrawal to avoid relapses and to improve the clinical benefit of the therapeutic approach. It has been also reported how the clinical results can be improved when traditional therapies are combined with behavioral approaches in particular mindfulness, that help patient to become more conscious about their symptoms and able to manage pain without medication. Generally patients after withdrawal follow a specific prophylaxis for migraine, but also come weekly to the hospital for practicing mindfulness for 6 sessionsAs the emergency situation due to the Corona-virus pandemic phenomenon in Italy, patients will miss the possibility to come for the regular practice to the hospital: for this reason the investigator propose a small pilot study to enforce the use of technology for our patients so that they can continue to be followed in their therapeutic process. This preliminary study will be conducted on 25 patients that have been submitted to a withdrawal according to the standard procedure at our hospital and they will practice mindfulness daily by a standard session of 12 minutes on their smartphone recorded by the expert who generally manage their sessions at the hospital and also a weekly video-call to evaluate the clinical condition and to encourage to use strategies for pain management. This modality will allow the patients to continue their therapeutic process and to be followed regularly during the one year after withdrawal

NCT04389372 Migraine Headache Behavioral: Mindfulness
MeSH:Migraine Disorders Headache
HPO:Headache Migraine

Primary Outcomes

Description: Changes in migraine /days per month and medication intake/month (decrease of at least 50% in at least 50% of CM-MO patients)

Measure: Efficacy of Mindfullness by Smartphone

Time: at 6 months and 12 months follow-up compared with baseline (Headache Daily Diary)

Secondary Outcomes

Description: Changes in disability, impact Migraine Disability Assessment Score (MIDAS questionnaire) minimum score 0-maximum score 270 HIGHER SCORES worse outcome (they indicate more disability)

Measure: Change of Disability Score

Time: 6months - 12months

Description: Changes in Headache Impact Test (HIT-6) minimum score 36- maximum score 78 HIGHER SCORES worse outcome (they indicate more impact)

Measure: Change in Quality of life

Time: 6months - 12 months

2 Home-withdrawal Program Combined With Behavioural Approach in Patients With Medication Overuse Headache During Covid-19 Emergency: Incidence of Relapses in Overuse and Changes in Impact at One Year Follow up

Medication Overuse Headache (MOH) is a disabling condition that affects the 2% of migraine population. Medication overuse (MO) makes this condition very difficult to treat. The literature of the last decades confirm the efficacy of withdrawal for patients with medication overuse, but it is also confirmed that patients have to be carefully followed after withdrawal to avoid relapses and to improve the clinical benefit of the therapeutic approach. Clinical results can be improved when traditional therapies are combined with behavioral approaches in particular mindfulness, that help patient to become more conscious about their symptoms and able to manage pain without medication. As the emergency situation due to the Corona-virus pandemic phenomenon in Italy, the regular clinical practice adopted for patients with CM-MO has changed in the last weeks: patients cannot come to the hospital for the withdrawal iv therapy and for regular follow up as the reduced mobility due to the emergency in particular in the Lombardia region, but all over Italy. So the investigators propose a pilot study to enforce the application of a Home-program for the withdrawal procedure for patients and the use of technology like smartphone and video calls so that patients can continue to be followed in their therapeutic process by using behavioral support and mindfulness practice. Patients will perform the withdrawal program at home, by oral administration of therapies, with specific instructions and education. Also the information for behavioral approach and mindfulness practice will be given, to use every day at home. Daily standardized mindfulness sessions of 12 minutes on their smartphone will be combined with weekly video-call to evaluate the clinical condition and to encourage the use strategies for pain management. Face-to-face visits at the follow up every three months will be scheduled. This modality will allow the patients to continue their therapeutic process and to be regularly followed during the one year after withdrawal.

NCT04410536 Migraine, Hemicrania Drug: Symptomatic drugs Drug: Bridge therapy Behavioral: Mindfulness program
MeSH:Headache Disorders, Secondary Migraine Disorders Emergencies Headache
HPO:Headache Migraine

Primary Outcomes

Description: Drop-out rates after withdrawal treatment

Measure: Drop out rates

Time: at 12 months

Secondary Outcomes

Description: Percentages of patients with absence of Medication Overuse Headache

Measure: Absence of Medication Overuse Headache (MOH)

Time: at 12 months from withdrawal program (assessed by Daily Diary Card)


HPO Nodes


HP:0002315: Headache
Genes 398
TWIST1 RSPH1 SPAG1 VHL JAK2 MVK COX1 SH2B3 SCN8A FGFR2 EPCAM DNAH1 NF1 NOTCH3 MEFV IL12A-AS1 GABRG2 CASP10 CTLA4 SLC6A19 RELA MLX RPL5 RRM2B THPO ADA2 DNAAF1 TRNC DNAH9 CCR1 BRAF RSPH4A TRNK TRNL1 ND4 PDGFB PRRT2 CYP11B2 MLH3 MSH2 KLRC4 KCNQ3 GAS8 ACVRL1 CCDC65 TRNQ AKT1 EGF CFI SCN1A MARCHF6 MYD88 FASLG COX3 TREX1 SDHA C4A CORIN RPS28 SCN8A RPL11 COL4A1 SLC25A11 CCM2 DNAAF6 TRNQ MPL CCDC103 SPP1 RNASEH2B DNAAF4 HLA-DPB1 PRRT2 SUFU TRNS1 SDHC ESR1 TWNK TP53 SOST TRNH NAGS HTRA1 NF2 FAS SDHD IL12A RET LPIN2 FOXJ1 POLG SMO DLST NF2 MYORG TET2 TRNW GCDH ADA2 DNAL1 VANGL1 PDGFRB BAP1 SDHB STAT4 KCNA1 KIT PEX11B FGFR2 RSPH9 NFIX IL23R ERF ERAP1 RPS27 RPS7 SMAD4 CFH NOP56 TRNS2 ADAR DKK1 IFIH1 EPM2A COX1 MSH6 PMS1 TNF POLG ATP1A2 SMARCB1 ND5 SOST FGFR3 MSX2 SDHB IRAK1 MEN1 EPOR PRTN3 UNC93B1 ALX4 DNAI1 MDH2 ND6 DNAJB13 RRM2B DNMT3A CNNM2 HLA-B CNNM2 RPS17 RET C11ORF95 SLC2A1 RNASEH2C TGFB1 RPL35A RPS20 LRRC6 NOTCH3 COX2 DNAAF5 CCNO COL5A2 RET STOX1 RPL31 RPL15 PTEN PRRT2 ATP6 LRRC56 FAS CYP11B1 NLRP3 RPL27 DNM1L ND6 AMACR ADA2 DNAAF3 SLC25A4 TRNL1 RASA1 ND1 OPA1 NLRP12 CYB5R3 JAK2 ADRA2B TREX1 RPS24 MCIDAS GATA1 SLC1A3 SDHB SDHAF2 CCM2 VHL PMS2 PGK1 CSNK1D TRNF CTNNB1 MSX2 PDCD10 CFAP221 AMER1 NF2 RPS26 GP1BA PIGT RPGR STK36 AP2S1 PRRT2 PDCD10 RPL26 PIK3CA RPS29 OFD1 SDHD ACVRL1 ND1 SDHD NME8 SDHC FH SCN2A SAMHD1 LRP5 SLC2A1 COX3 GPR101 CFAP298 SLC2A1 RPS10 CFAP300 PGK1 SPEF2 FARSB CYTB ZMYND10 TRNV AIP NLRP3 TGFBR2 FLT1 RNASEH1 CCDC39 ARMC4 HLA-B TNFRSF1A UBAC2 APP FAS DNAI2 POLG NEK10 POLG EPAS1 DNAI1 CDH23 PTPN22 SEMA4A TWNK KYNU POLG2 KRIT1 PDGFB TRNS2 KCNQ2 VHL TLR3 NDP TRAF3 CDC73 CACNA1A TRAF7 HTR1A F8 HLA-DPA1 MPL TLR4 CTNND2 PIK3CA SOST SLC12A3 NLRP3 FAN1 NOTCH2 BAP1 TWNK TICAM1 CACNA1A RPS15A TERT ENG LRP5 TTR COX2 TRNF GAS2L2 MVK BMPR1A FLI1 GDF2 KIF23 CCDC151 APP SLC2A1 CACNA1A ZFHX2 SRPX2 CLCNKB CDC73 FGFR3 IRF3 IL10 IL12B RASGRP1 GRIN2A RPL18 STAT4 RNF168 SH2B1 NHLRC1 DNAH5 TSR2 APC ACSF3 CDH23 COL5A1 SMARCB1 TTC12 PTPN22 TWNK TRNW CACNA1A TMEM127 ADAMTSL1 GATA2 MLH1 CLCN2 TBK1 ADA2 KRAS CCDC40 ND5 SMAD3 SLC1A3 COL1A1 NLRP3 MSX2 YEATS2 TREX1 PRKAR1A GP1BB RPL35 F8 TTC25 DNAAF2 HELLPAR MAX DRC1 KIF1B CACNA1A RSPH3 SAMD12 APP TRNS1 AIP GP9 RNASEH2A KCNA1 HYDIN KCNA1 EDNRA CDH23 RPS19 CNTN2 SMARCE1 CD46 CCDC114 KCNJ5 MAOA ENG CACNA1D KRIT1 PRKCD STIM1 SLC19A2 VHL USP8 COL3A1 JAK2 DNAH11
Protein Mutations 0
SNP 0